以岭药业（002603）8月15日主力资金净流出2481.46万元

Group 1 - The core viewpoint of the articles highlights the financial performance and market activity of Yiling Pharmaceutical Co., Ltd. as of August 15, 2025, indicating a mixed performance with a slight increase in stock price but a decrease in revenue [1][3] - As of the first quarter of 2025, the company's total operating revenue was 2.358 billion yuan, a year-on-year decrease of 6.52%, while the net profit attributable to shareholders was 326 million yuan, reflecting a year-on-year increase of 7.25% [1] - The company has a current ratio of 1.802, a quick ratio of 1.281, and a debt-to-asset ratio of 23.13%, indicating a stable liquidity position and low leverage [1] Group 2 - Yiling Pharmaceutical has made investments in 17 companies and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 628 trademark registrations and 597 patent registrations, indicating a strong focus on intellectual property [2] - Additionally, Yiling Pharmaceutical has obtained 739 administrative licenses, reflecting its compliance and operational capabilities [2]